Olivier Dupuis

TL;DR: The benefit of oxaliplatin was not demonstrated and this drug should not be used with concurrent irradiation, and Cap 50 merits investigation for T3-4 rectal cancers.

TL;DR: The planned complete discontinuation of chemotherapy had a negative impact on DDC and PFS compared with the maintenance therapy strategy, suggesting that chemotherapy discontinuation cannot be decided before therapy is initiated in patients with advanced colorectal cancer.

TL;DR: Results indicate that concurrent administration of oxaliplatin and RT is not recommended in preoperative chemoradiotherapy in T3-4 Nx M0 resectable rectal cancer, when compared with other recent randomized trials.

TL;DR: IDA France, in which 90% of patients received mFOLFOX6, shows superiority of 6 months of adjuvant chemotherapy compared with 3 months, especially in the T4 and/or N2 subgroups, and should be considered alongside the international IDEA collaboration data.

TL;DR: This randomised, open-label, phase 3 study assessed whether the combination of erlotinib, an EGFR tyrosine kinase inhibitor, with bevacizumab could increase the efficacy of maintenance therapy in patients with unresectable metastatic colorectal cancer.